Bulletin
Investor Alert

Forte Biosciences Inc.

NAS: FBRX

GO
/marketstate/country/us

After Hours

 --Real time quotes

May 16, 2022, 7:23 p.m.

/zigman2/quotes/210207744/composite

$

1.07

Change

-0.0050 -0.47%

Volume

Volume 3,234

Real time quotes

/zigman2/quotes/210207744/composite

Today's close

$ 1.18

$ 1.08

Change

-0.11 -8.90%

Day low

Day high

$1.06

$1.18

Open

52 week low

52 week high

$1.06

$43.57

Open

Company Description

Forte Biosciences, Inc. is a biopharmaceutical company, which engages in the provision of dermatology products and services. The firm's lead product includes FB-401, which is a live biotherapeutic for the treatment of inflammatory skin disease, including pediatric and adult patients with atopic derm...

Forte Biosciences, Inc. is a biopharmaceutical company, which engages in the provision of dermatology products and services. The firm's lead product includes FB-401, which is a live biotherapeutic for the treatment of inflammatory skin disease, including pediatric and adult patients with atopic dermatitis. The company was founded by Paul A. Wagner in 2017 and is headquartered in Dallas, TX.

Valuation

Price to Book Ratio

0.76

Enterprise Value to EBITDA

1.15

Efficiency

Liquidity

Current Ratio

24.19

Quick Ratio

24.19

Cash Ratio

23.92

Profitability

Return on Assets

-41.53

Return on Equity

-43.19

Return on Total Capital

-42.75

Capital Structure

Officers and Executives

Name Age Officer Since Title
Dr. Paul A. Wagner 50 2017 President, Chief Executive Officer & Director
Mr. Anthony A. Riley - 2020 Chief Financial Officer
Dr. Daniel J. Burge 58 - Head-Clinical Development
Mr. Steven J. Ruhl - 2021 Chief Technical Officer
Dr. Barbara K. Finck 74 2022 Director

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
09/07/2021 Paul A. Wagner
See Remarks; Director
1,000,000   Disposition at $4.35 per share. 4,350,000
09/07/2021 Anthony A. Riley
Chief Financial Officer
3,516   Disposition at $4.27 per share. 15,013
09/07/2021 Anthony A. Riley
Chief Financial Officer
21,484   Disposition at $4.24 per share. 91,092
01/13/2021 Thomas E. Darcy
Director
500   Derivative/Non-derivative trans. at $9.59 per share. 4,795
06/29/2020 Anthony A. Riley
Chief Financial Officer
2,000   Acquisition at $14.11 per share. 28,220
06/26/2020 Anthony A. Riley
Chief Financial Officer
4,700   Acquisition at $14.52 per share. 68,244
06/25/2020 Paul A. Wagner
See Remarks; Director
7,000   Acquisition at $14.48 per share. 101,360
04/14/2020 Steven M. Oliveira
74,301   Acquisition at $1.19 per share. 88,418
03/02/2020 Steven M. Oliveira
65,149   Acquisition at $1.35 per share. 87,951
02/26/2020 Harry E. Gruber
President, Science&Innovation; Director
13,941   Award at $0 per share. 0
05/30/2019 Faheem Hasnain
Director
250   Acquisition at $5.15 per share. 1,287
05/30/2019 Faheem Hasnain
Director
3,890   Acquisition at $5.3 per share. 20,617
05/30/2019 Faheem Hasnain
Director
38,860   Acquisition at $4.59 per share. 178,367
05/28/2019 Mark G. Foletta
EVP & Chief Financial Officer
5,000   Acquisition at $4.3 per share. 21,500
05/28/2019 Martin J. Duvall
Chief Executive Officer; Director
5,000   Acquisition at $4.34 per share. 21,700
/news/latest/company/us/fbrx

MarketWatch News on FBRX

  1. Forte Biosciences downgraded to neutral from buy at B. Riley

    7:53 a.m. Sept. 3, 2021

    - Tomi Kilgore

  2. Forte Biosciences stock price target cut to $3 from $73 at B. Riley

    7:53 a.m. Sept. 3, 2021

    - Tomi Kilgore

  3. Forte Biosciences started at buy with $73 stock price target at B. Riley

    7:48 a.m. May 14, 2021

    - Tomi Kilgore

  4. Forte Biosciences initiated at buy with $70 price target at Truist Securities

    8:29 a.m. Aug. 25, 2020

    - Tonya Garcia

  5. Tocagen stock price target cut to $1 from $22 at B. Riley FBR

    7:19 a.m. Sept. 13, 2019

    - Tomi Kilgore

  6. Tocagen downgraded to neutral from buy at B. Riley FBR

    7:19 a.m. Sept. 13, 2019

    - Tomi Kilgore

  7. Tocagen downgraded to in line from outperform at Evercore ISI

    11:05 a.m. Sept. 12, 2019

    - Tomi Kilgore

  8. Tocagen price target lowered to $5 from $11 at SVB Leerink

    7:53 a.m. May 10, 2019

    - Tonya Garcia

  9. Tocagen started at market perform with $11 stock price target at SVB Leerink

    7:53 a.m. April 15, 2019

    - Tomi Kilgore

  10. Tocagen started at outperform with $28 stock price target at Evercore ISI

    4:20 p.m. May 8, 2017

    - Tomi Kilgore

  11. Tocagen started at buy with $24 stock price target at Stifel Nicolaus

    7:15 a.m. May 8, 2017

    - Tomi Kilgore

  12. Four Small Biotechs See Bullish April Stock Buys

    5:51 a.m. May 3, 2017

    - Barron's Online

  13. Gene therapy company Tocagen prices offering at low end of range

    8:43 a.m. April 13, 2017

    - Caitlin Huston

  14. Tocagen prices IPO at $10 a share

    8:31 a.m. April 13, 2017

    - Ciara Linnane

/news/nonmarketwatch/company/us/fbrx

Other News on FBRX

  1. 10-Q: FORTE BIOSCIENCES, INC.

    8:36 a.m. Today

    - Edgar Online - (EDG = 10Q, 10K)

  2. 10-Q: FORTE BIOSCIENCES, INC.

    10:03 a.m. Nov. 8, 2021

    - Edgar Online - (EDG = 10Q, 10K)

  3. Warning: FBRX is at high risk of performing badly

    6:18 a.m. Nov. 2, 2021

    - Seeking Alpha

  4. Warning: FBRX is at high risk of performing badly

    4:55 a.m. Nov. 2, 2021

    - Seeking Alpha

  5. BiomX: Undervalued With Multiple Upcoming Catalysts

    6:42 p.m. Oct. 6, 2021

    - Seeking Alpha

  6. Wall Street Breakfast: What Moved Markets

    8:25 a.m. Sept. 4, 2021

    - Seeking Alpha

  7. JOBY, FTFT and CLIR among mid-day movers

    12:34 p.m. Sept. 3, 2021

    - Seeking Alpha

  8. Why Forte Biosciences Stock Is Imploding Today

    11:21 a.m. Sept. 3, 2021

    - Motley Fool

  9. Forte Bio draws downgrades after setback in dermatitis trial

    3:11 a.m. Sept. 3, 2021

    - Seeking Alpha

  10. Loading more headlines...

At a Glance

Forte Biosciences, Inc.

3060 Pegasus Park Drive

Building 6

Dallas, Texas 75247

Phone

1 3106186994

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2022

Revenue

N/A

Net Income

$-21.71M

Employees

5.00

/news/pressrelease/company/us/fbrx

Press Releases on FBRX

  1. Forte Biosciences, Inc. Announces First Quarter 2022 Results and Provides Business Update

    9:00 a.m. Today

    - BusinessWire - BZX

  2. Best Penny Stocks to Buy Today? 3 to Watch on May 3rd

    9:34 a.m. May 3, 2022

    - Penny Stocks

  3. Forte Trials Falters, Stock Punished

    10:42 a.m. Sept. 3, 2021

    - Baystreet.ca

Link to MarketWatch's Slice.